Cizzle Bio Supports Early Cancer Detection at Prevent Cancer Foundation’s 2026 Gala
Cizzle Biotechnology PLC Executive Chairman Dr. Allan Syms; Cizzle Bio Inc. Founder and CEO Bill Behnke; and national patient advocate, Gerry McDougall, chairman of the Multiple Myeloma Research Foundation and board member of Conquer Cancer, the ASCO Foundation
Cizzle Bio served as a sponsor of the Prevent Cancer Foundation® 32nd Annual Gala, held September 16 at the National Building Museum in Washington, D.C. The event brought together leaders in cancer research, healthcare, advocacy, government, and philanthropy around a shared goal: advancing cancer prevention and early detection.
More than 800 guests attended the 2026 Gala, helping raise over $2 million for prevention and early detection initiatives. Founder and CEO Bill Behnke also served on the Gala Committee, supporting the event and its mission. His participation reflects a commitment shaped by both Cizzle Bio’s work and his family’s personal experience with cancer.
The partnership aligns closely with Cizzle Bio’s focus on improving cancer detection through biomarker-based blood tests. The company’s flagship CIZ1B Biomarker Blood Test is designed to complement standard-of-care lung cancer diagnostics by giving physicians additional biomarker information to support clinical decision-making.
By supporting the Prevent Cancer Foundation, Cizzle Bio joins a broader community working to expand access, strengthen research and improve outcomes for patients and families through earlier detection.
Read the full press release for more about the Gala, its honorees and Cizzle Bio’s commitment to advancing earlier cancer detection.
